This technology identifies a diagnostic DNA sequence of a gene implicated in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS), which could be used to distinguish IC/BPS from other urological conditions, such as chronic urinary tract infections (UTIs).
Interstitial cystitis/bladder pain syndrome (IC/BPS) is currently diagnosed through clinical evaluation and exclusion of other conditions, as its symptoms overlap with those of other urological disorders, such as chronic urinary tract infections (UTIs). The lack of validated molecular biomarkers complicates diagnosis, potentially leading to prolonged diagnostic uncertainty and unnecessary treatment. Reliable diagnostic tools are needed to distinguish IC/BPS from other bladder pathologies and enable more appropriate clinical management.
This technology identifies a DNA sequence of a gene implicated in interstitial cystitis/bladder pain syndrome (IC/BPS). The mutant sequence of this gene could potentially be used in molecular diagnostic assays to distinguish IC/BPS from other urological conditions with overlapping symptoms, including chronic urinary tract infections (UTIs). This approach may complement existing clinical diagnostic methods and support more accurate differential diagnosis of IC/BPS.
Patent Pending